Lisa Turner

Lisa Turner, RPh, Vice President, Clinical & Medical for OrphoMed, has over 25 years of experience in the pharmaceutical industry. Before joining OrphoMed in 2017, she served as Executive Director, Clinical Operations for Furiex Pharmaceuticals, where she was responsible for advancing an antibiotic program from Phase 1 to Phase 2/3 clinical development and for managing one of Phase 3 clinical trials for eluxadoline. In 1991, Ms. Turner joined Pharmaceutical Product Development (PPD), a contract research organization. At PPD, as a member of the compound partnering group, she served as program lead for two compounds, participated in technical due diligence for numerous compounds, and helped create development programs for compounds of interest. At PPD, she also served as Chair of the Global Steering Committee, where she facilitated the global implementation of an internal project management system, and she managed the General Medicine division for several years. Ms. Turner is a registered pharmacist who has practiced in retail and hospital settings. She has a BS in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill.